Ajanta Pharma’s Paithan facility in Aurangabad has been issued one observation from the US health regulator. The Paithan facility was recently inspected by the US Food and Drug Administration (USFDA) and had been issued one procedural related ‘483’. The company is in the process of responding to the same within the stipulated time prescribed by USFDA.
Ajanta Pharma is a specialty pharmaceutical formulation company with global headquarters in Mumbai, India. The company is engaged in developing, manufacturing and marketing of quality finished dosages across 30+ countries.
